Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R
Department of Internal Medicine, University of Innsbruck Medical School, Austria.
Br J Haematol. 1998 Sep;102(4):1069-80. doi: 10.1046/j.1365-2141.1998.00880.x.
It has been shown that granulocyte/macrophage colony stimulating factor (GM-CSF) is able to support myeloma cell propagation in cooperation with interleukin (IL)-6, the major growth factor for malignant plasma cells, although the biological mechanisms involved remain unknown. Therefore we investigated (i) the expression levels of the GM-CSF receptor (GM-CSFR) constituents in three malignant plasma cell lines and in native malignant plasma cells, (ii) the ability of the receptor to mediate common signalling pathways regulating proliferation and cell survival in malignant plasma cell lines, and (iii) the effects of GM-CSF on tumour cell biology. The GM-CSFRalpha subunit was detected in the malignant plasma cell lines RPMI-8226, MC/CAR, IM-9 as well as 6/6 native myeloma cell samples derived from the bone marrow of patients with overt disease. Furthermore, GM-CSFR expression was also detected in the CD19+ fraction from 2/3 bone marrow samples and 5/8 peripheral blood samples derived from patients with malignant plasma cell disorders, but not in the CD19+ fraction of peripheral blood from healthy donors. The expressed cytokine receptor alpha-subunit was able to constitute a functional signalling complex with the ubiquitously expressed GM-CSFRbeta subunit, as demonstrated by the fact that GM-CSF induced the p21-ras/mitogen-activated protein kinase (MAPK) signalling cascade in malignant plasma cell lines. Since this signalling cascade plays an essential role in the mediation of both proliferation and cell survival, we investigated the impact of GM-CSF on these two events. Application of GM-CSF led to an increase of DNA-synthesis in MC/CAR, IM-9 and RPMI-8226 cells. Furthermore, it increased longevity of these malignant plasma cell lines by reducing the rates of spontaneous apoptosis. We conclude that (i) the functional GM-CSFR is commonly expressed on malignant plasma cells and that (ii) GM-CSF promotes the clonal expansion of myeloma cells by inhibiting spontaneous apoptosis and promoting DNA synthesis.
研究表明,粒细胞/巨噬细胞集落刺激因子(GM-CSF)能够与白细胞介素(IL)-6协同支持骨髓瘤细胞的增殖,IL-6是恶性浆细胞的主要生长因子,但其涉及的生物学机制尚不清楚。因此,我们研究了:(i)GM-CSF受体(GM-CSFR)成分在三种恶性浆细胞系和天然恶性浆细胞中的表达水平;(ii)该受体介导调节恶性浆细胞系增殖和细胞存活的常见信号通路的能力;(iii)GM-CSF对肿瘤细胞生物学的影响。在恶性浆细胞系RPMI-8226、MC/CAR、IM-9以及6/6份来自显性疾病患者骨髓的天然骨髓瘤细胞样本中检测到了GM-CSFRα亚基。此外,在2/3份来自恶性浆细胞疾病患者的骨髓样本和5/8份外周血样本的CD19+组分中也检测到了GM-CSFR表达,但在健康供体外周血的CD19+组分中未检测到。表达的细胞因子受体α亚基能够与普遍表达的GM-CSFRβ亚基构成功能性信号复合物,这一事实表明GM-CSF在恶性浆细胞系中诱导了p21-ras/丝裂原活化蛋白激酶(MAPK)信号级联反应。由于该信号级联反应在增殖和细胞存活的介导中起着至关重要的作用,我们研究了GM-CSF对这两个事件的影响。GM-CSF的应用导致MC/CAR、IM-9和RPMI-8226细胞中DNA合成增加。此外,它通过降低自发凋亡率提高了这些恶性浆细胞系的寿命。我们得出结论:(i)功能性GM-CSFR在恶性浆细胞上普遍表达;(ii)GM-CSF通过抑制自发凋亡和促进DNA合成促进骨髓瘤细胞的克隆扩增。